Clinical Report: Comprehensive Multi-Omics Investigation of Wilms Tumor
Overview
This study identifies distinct molecular subtypes of Wilms tumor (WT) related to stemness and prognosis, revealing APCDD1 as an epigenetic target and Leflunomide as a potential therapeutic agent. The findings enhance understanding of WT biology and propose actionable insights for risk stratification.
Background
Wilms tumor is the most prevalent pediatric renal malignancy, with a significant proportion of patients facing refractory disease and poor long-term survival. Understanding the molecular mechanisms of WT is essential for improving treatment strategies and outcomes. This study employs multi-omics approaches to elucidate the role of stemness in WT and identify potential therapeutic targets.
Data Highlights
No numerical data provided in the source material.
Key Findings
Blastemal cells in WT exhibit the highest stemness score, correlating with worse prognosis.
WT samples were stratified into two molecular subtypes (C1 and C2) based on stemness-related genes.
The C1 subtype is characterized by higher stemness and an immunosuppressive tumor microenvironment.
APCDD1 acts as a tumor suppressor, with its expression restored by the demethylating agent Decitabine.
Leflunomide demonstrated significant inhibition of WT cell proliferation, migration, and invasion in vitro.
A robust prognostic risk signature was developed using Lasso-Cox regression analysis.
Clinical Implications
The identification of distinct molecular subtypes and prognostic indicators in WT can guide risk stratification and treatment decisions. The potential use of Leflunomide may offer a new therapeutic strategy for high-risk WT patients.
Conclusion
This comprehensive investigation into the molecular landscape of Wilms tumor provides critical insights into its biology and highlights APCDD1 and Leflunomide as key targets for future research and clinical application.
